Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851838 | 0.88 | CA1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL403705 | 0.86 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL70172 | 0.82 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4470759 | 0.81 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15445363 | 0.81 | ALDH1A1 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30368137 | 0.81 | CA1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1962462 | 0.81 | CA1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4144207 | 0.81 | CA1 (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16056668 | 0.80 | GRM6 (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1648531 | 0.80 | CA12 (0.44) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854631-B | 4-Aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2025-04-15 | — | — | CN | claimed |
| CN-116854631-A | 4-aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2023-10-10 | — | — | CN | claimed |
| EP-4703358-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | China Pharmaceutical University (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025223904-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640052-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025133395-A1 | BICYCLIC (HETERO)ARYLENE WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| CN-116854631-B | 4-Aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-1611098-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2005021532-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005012286-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004089897-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
| US-4359568-A | LAMINATING RESINS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1982-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | CA12 2818/4885CA1 2266/4885CA2 1909/4885 |
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | CA12 1787/4885CA1 738/4885CA2 1765/4885 |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | CA12 4873/4885CA1 4884/4885CA2 4751/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | CA12 2809/4885CA1 4723/4885CA2 4475/4885 |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | VHL, DPYD, UGT1A1 | CA12 2294/4885CA1 3550/4885CA2 1834/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | CA12 4877/4885CA1 4751/4885CA2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.